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This study reports on the in vivo effects of four endomorphin-2 (EM-2) derivatives (EMD1-4) containing unnatural 
amino acids, i.e. 2-aminocyclohexanecarboxylic acid (Achc2), para-fluorophenylalanine (pFPhe4), β-methyl-
phenylalanine (βMePhe4) and/or 2’,6’-dimethyltyrosine (Dmt1). After induction of osteoarthritis by monosodium 
iodoacetate into the ankle joint of male Wistar rats, a chronic intrathecal catheter was inserted for spinal drug 
delivery. The mechanical threshold was assessed by a dynamic aesthesiometer. Intrathecal injection of the original 
EM-2 and the ligands (0.3–10 µg) caused dose-dependent antiallodynic effects. The comparison of the different 
substances revealed that EMD3 and EMD4 showed more prolonged antinociception than EM-2, and the effects of 
the highest dose of EMD4 were comparable to morphine, while EMD3 caused paralysis at this dose. The potency of 
the different ligands did not differ from EM-2. The results show that the derivatives of EM-2 have similar in vivo 
potency to the original ligand, but their effects were more prolonged suggesting that these structural modifications 
may play a role in the development of novel endomorphin analogues with increased therapeutic potential. 
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Morphine and related compounds that are clinically valuable for pain relief, act primarily at 
the μ-opioid receptor (MOR), a member of the G-protein-coupled receptor superfamily (39). 
A major goal in opioid peptide research is the development of novel analgesics that could 
substitute for morphine without its well-known side effects of dependence, tolerance, 
respiratory depression and reward-seeking behavior (25). The study of naturally occurring 
peptides provides a rational and powerful approach in the design of peptide medications. 
Endomorphin-1 (EM-1, Tyr-Pro-Trp-Phe-NH2) and endomorphin-2 (EM-2, Tyr-Pro-Phe-
Phe-NH2) are high-affinity, MOR-selective endogenous opioids which also inhibit nociception 
similarly to opiates of plant origin in both acute and chronic pain models (10, 31, 44). The 
exogenous application of EMs encounters serious limitations, including a short duration of 
action, a lack of activity after oral administration and poor metabolic stability (23, 34, 37). 
Aminopeptidases play a key role in the biodegradation of EMs, during which the main 
cleavage occurs at the Pro2-Trp3 and Pro2-Phe3 peptide bonds. For their consideration as actual 
therapeutic drugs it is essential to enhance their resistance to enzymatic degradation (12). 
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Such objectives may possibly be achieved through systematic modification of the peptide 
sequence (9, 11, 15). 
The solution structures of the EMs and their analogues have been investigated in 
detail in relation to their bioactivity (15). In a recent paper, the synthesis and structure-
activity study of new analogues with unnatural amino acids were reported (22). The 
systematic replacement of natural amino acids by 2’,6’-dimethyltyrosine (Dmt1), 2-amino-
cyclohexanecarboxylic acid [cis-(1S,2R)Achc2/cis-(1R,2S)Achc2], β-methylphenylalanine 
[(2R,3R)βMePhe4/(2S,3S)βMePhe4] and para-fluorophenylalanine (pFPhe4) in different 
positions resulted in proteolytically stable compounds with high MOR affinity in some cases 
(22). Thus, it was found that the analogues carrying Dmt1 and Achc2 residues displayed 
the highest MOR affinities, depending upon the configuration of the incorporated Achc2. 
Combination of such derivatives with pFPhe4 or βMePhe4 yielded compounds with high 
binding potency, while their efficacy did not differ from the parent ligand. Several earlier 
studies investigated the in vivo activities of different endomorphin derivatives in acute heat 
or chemical pain models (2, 17, 24, 27, 45). The goal of this study was to investigate the 
antiallodynic effects of the recently synthetized and most potent EM-2 derivatives (EMD1-4, 
Table I) at spinal level, in a chronic joint pain model.
Materials and Methods
Animals
After institutional ethical approval had been obtained (Institutional Animal Care Committee 
of the Faculty of Medicine at the University of Szeged), male Wistar rats (Charles River 
strain, Bioplan, Budapest, Hungary; 334 ± 3.8 g; n = 7–14 / group) were housed in groups of 
5–6 per cage, with free access to food and water, and with a natural light/dark cycle.
Drugs
The following drugs were purchased: ketamine hydrochloride (Calypsol, Richter Gedeon RT, 
Budapest, Hungary), xylazine hydrochloride (Rompun, Bayer, Leverkusen, Germany), 
Gentamycin (Sanofi-Aventis, Budapest, Hungary), monosodium iodoacetate (MIA; Sigma-
Aldrich Ltd. Budapest, Hungary) and morphine hydrochloride (Hungaropharma, Budapest, 
Hungary). EM-2 and the derivatives (Table I) were synthesized as was described earlier (22). 
All substances were dissolved in saline. Intrathecally (i.t.) administered drugs were injected 
over 120 s in a volume of 10 µl, followed by a 10 µl flush of physiological saline. 
Abbreviations
 
Achc = 2-aminocyclohexanecarboxylic acid 
ANOVA = analysis of variance 
AUC = area under the curve 
βMePhe = β-methylphenylalanine 
CI = 95% confidence intervals 
Dmt = 2’,6’-dimethyltyrosine 
ED25 = 25% effective dose 
EM-1 = endomorphin-1 (Tyr-Pro-Trp-Phe-NH2) 
EM-2 = endomorphin-2 (Tyr-Pro-Phe-Phe-NH2) 
EMD1 = Tyr-(1S,2R)Achc-Phe-pFPhe-NH2 
EMD2 = Tyr-(1S,2R)Achc-Phe-(2S,3S)bMePhe-NH2 
EMD3 = Dmt-(1S,2R)Achc-Phe-pFPhe-NH2
EMD4 = Dmt-(1S,2R)Achc-Phe-(2S,3S)bMePhe-NH2 
HP = hot-plate 
i.t = intrathecally 
i.c.v. = intracerebroventrical 
MOR = μ-opioid receptor 
%MPE = % maximum possible effect 
pFPhe = para-fluorophenylalanine 
TF = tail-flick
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Monosodium iodoacetate-induced inflammation
Osteoarthritis was induced by injecting MIA (1 mg / 30 µl) into the tibiotarsal joint of the 
right hind leg on two consecutive days. All treatments were given to gently restrained 
conscious animals, using a 27-gauge needle, without anaesthesia so as to exclude any drug 
interaction. These injections did not elicit signs of major distress. Animals were allowed to 
recover for 14 days, which has consistently been shown to cause severe end-stage cartilage 
destruction resulting in osteoarthritis-like joint pain (3, 13). 
To determine the changes in the size of the inflamed joint, we measured the anteroposterior 
and mediolateral diameter of the paw at the level of ankle joint with a digital caliper. The 
cross-section area was calculated with the formula a × b × π, where a and b are the radii in 
the two aspects. 
Intrathecal catheterization
Two weeks after MIA administration rats were anaesthetized with a mixture of ketamine 
hydrochloride and xylazine (72 and 8 mg/kg intraperitoneally: i.p., respectively). An i.t. 
catheter (PE-10 tubing; Intramedic, Clay Adams; Becton Dickinson; Parsippany, NJ; I.D. 
0.28 mm; O.D. 0.61 mm) was inserted via the cisterna magna and passed 8.5 cm caudally into 
the subarachnoid space (42), which served to place the catheter tip between Th12 and L2 
vertebrae, corresponding to the spinal segments that innervate the hindpaws (6). After 
surgery, rats were housed individually and had free access to food and water. Animals 
exhibiting postoperative neurologic deficits (about 10%), and also those that did not show 
paralysis of one of the hindpaws after the administration of 100 µg lidocaine (about 0.5%) 
were excluded (6). After the surgery, animals were administered antibiotics (13 mg/kg 
gentamicin, subcutaneously) to prevent infection. The rats were allowed to recover for at 
least four days before testing, and were assigned randomly to the treatment groups. The 
observer was blind to the treatment administered. Repeated intrathecal injections in the same 
animals were separated by 5–7 days.
Behavioral nociceptive testing
Mechanical allodynia was determined using a dynamic plantar aesthesiometer (Ugo Basile, 
Comerio, Italy). Prior to baseline testing, each rat was habituated to a testing box with a wire-
mesh grid floor for at least 20 min. Measurements were done with a straight metal filament 
that exerts an increasing upward force at a constant rate (4.25 g/s) with a maximum cut-off 
force of 50 g. The filament was placed under the plantar surface of the hind paw. Measurement 
was stopped when the paw was withdrawn, and results were expressed as paw withdrawal 
thresholds in grams.
Experimental protocol
After baseline determination of tibiotarsal joint diameter and mechanical paw withdrawal 
threshold (pre-MIA baseline values at 1st day), MIA was injected. These measurements were 
repeated 7 and 14 days later, and then the intrathecal catheterization was performed. One 
week later the non-paralysed rats were selected and after the post-MIA baseline value 
determination, the different ligands were administered (Table I). The control group received 
physiological saline. In the positive control group, animals were treated with 10 µg morphine. 
The pain thresholds were registered 10, 20, 30, 45, 60, 75, 90, 105 and 120 min after the 
intrathecal injection, and the mean of the values obtained between 10–30, 45–75 and 90–120 
min were analyzed.
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At the end of the experiment, the joint diameters were measured again. We did not 
examine the motor behavior systematically, nor did we quantify it, but the animals’ behaviors 
were observed, and in most animals there were no signs of altered behavior (immobility, 
flaccidity, excitation or motor weakness), except for the administration of 10 µg EMD3 
which produced paralysis. Animal suffering and the number of animals per group were kept 
at a minimum.
Statistical analysis
Data are presented as means ± SEM. Paw withdrawal thresholds on the inflamed side were 
transformed to % maximum possible effect (%MPE) by the following formula:
%MPE = (observed threshold – post-MIA baseline threshold) / (50 – post-MIA baseline 
threshold) × 100.
Therefore, 100% MPE means perfect relief of allodynia (equivalent to cut-off value [50 
g] for all measurements), while 0% MPE means that the observed threshold is equivalent to 
the post-MIA baseline value. The time-course data sets were examined by two-way analysis 
of variance. The significance of differences between the different groups was calculated 
using the Fisher LSD test for post hoc comparison (p value < 0.05 was considered significant).
Area under the curve (AUC) values were obtained by calculating the area between 0 and 
120 min to construct dose response curves for different doses of ligands. AUC 5500 (AUCmax) 
value would mean the complete relief of hyperalgesia (50 g) during the whole period. We 
observed almost no effects regarding the AUC values after saline treatment (AUCmin = 2813 
± 227). The mean AUC values were used for linear regression analysis (least square method) 
to determine the ED25 values with 95% confidence intervals (CI). The 25% effective dose 
(ED25) means the dose that yielded 25 % increase in the PWD latency for the whole period 
(32). 
The AUC data sets were examined by one-way analysis of variance (ANOVA), and the 
time-course curves were analyzed by repeated measurement of ANOVA. Post hoc comparisons 
were carried out with the Fisher’s LSD test. Statistical analysis was performed with the 
STATISTICA for Windows (Statistica Inc., Tulsa, Oklahoma, USA) and GraphPad Prism 4.0 
(GraphPad Software Inc. La Jolla, CA, US) softwares.
Results
Joint edema
The MIA injection caused a permanent increase in joint cross-section area compared with the 
contralateral side (48.4 ± 0.37 vs. 38.3 ± 0.15 mm2, p < 0.01). This conspicuous increase in 
joint size was a result of edema formation, confirming that the MIA treatment resulted in an 
inflammatory reaction (1). None of the treatments influenced the degree of edema; the cross 
section of the ankle was 49.5 ± 0.53 mm2 at the end of the experiments, which did not differ 
from the post-MIA baseline value.
 
Mechanosensitivity
Basal mechanical withdrawal threshold was 41 ± 0.6 g, and MIA caused a significant decrease 
in paw withdrawal threshold on the inflamed side. This threshold was lowest after 1 week of 
MIA (15 ± 0.6 g), and later it stabilized at 24 ± 0.5 g. There was no significant difference 
between before and after intrathecal catheterization (p = 0.62), suggesting that the 
catheterization did not change the inflammatory pain sensitivity. MIA did not have a 
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significant influence on the non-inflamed side (43 ± 0.5 g). None of the treatments changed 
the mechanosensitivity on the non-inflamed side; therefore, results were analyzed only on the 
inflamed paws. 
All the drugs had antinoallodynic potency therefore, we compared the effects of different 
doses of the analogues with EM-2. As for the lowest dose (0.3 µg), ANOVA with repeated 
measurements showed significant effects of time (F2,104 = 9.6, p < 0.001) and interaction 
(F10,104 = 2.4, p < 0.05). The post hoc comparison revealed that EMD3 and EMD4 produced 
significant antinociception, while EM-2 and the other two ligands were ineffective in this 
dose (Fig. 1).
At 3 µg, all of the ligands produced antiallodynia. ANOVA with repeated measurements 
showed significant effects of treatment (F5,55 = 5.4, p < 0.001) and time (F2,110 = 5.6, p < 0.01). 
Post hoc comparison showed that EMD3 was more effective than EM-2 during the last 
investigated interval (75–120 min, Fig. 2). 
Regarding the highest dose, 10 µg of EMD3 caused prolonged paralysis of the animals, 
therefore, we could not analyze their data on the pain test. ANOVA with repeated measurements 
showed significant effects of treatment (F5,50 = 8.4, p < 0.001) and time (F2,100 = 19.8, p < 
0.001). Post hoc comparison showed that all the drugs were effective compared to the control 
group at the first and second investigation period, however, only EMD4 was effective during 
the whole period compared to both control and EM-2 treated groups (Fig. 3). Morphine, as a 
positive control, produced long-lasting and highly effective antinociception. EM-2, EMD1 
and EMD2 were effective as morphine only at the first investigated period (10–30 min), 
while the effect of EMD4 did not differ significantly from morphine during the whole period. 
Fig. 1. Time-course effects of EM2 and the derivatives at 0.3 µg dose.  
Each point signifies the mean ± SEM of the results. * indicates a significant (p < 0.05) difference as compared with 
the saline-treated group. # denotes a significant difference as compared with the EM-2-treated group
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Fig. 2. Time-course effects of EM2 and the derivatives at 3 µg dose.  
Each point signifies the mean ± SEM of the results. * indicates a significant (p < 0.05) difference as compared with 
the saline-treated group. # denotes a significant difference as compared with the EM-2-treated group
Fig. 3. Time-course effects of EM2, morphine and the derivatives at 10 µg dose.  
Each point signifies the mean ± SEM of the results. * indicates a significant (p < 0.05) difference as compared with 
the saline-treated group. # denotes a significant difference as compared with the EM-2-treated group
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As for the dose-response curves of the ligands, we observed that in the case of EMD3 
the steepness of the curve is higher, and the curve of EMD4 is also slightly left-shifted (Fig. 
4). However, the ED25 values did not reveal significant difference between these ligands 
(Table I). 
Table I. The applied drugs and their dosage, the number of animals in each group and in vivo potency 
Doses (µg) and number of animals
0 0.3 1 3 10 ED25 (CI) (µg)
Saline 8
EM-2: Tyr-Pro-Phe-Phe-NH2 8 8 9 6.3 [1.30–10.00]
EMD1: Tyr-(1S,2R)Achc-Phe-pFPhe-NH2 10 9 10 5.3 [1.73–8.85]
EMD2: Tyr-(1S,2R)Achc-Phe-(2S,3S)bMePhe-NH2 10 10 10 7.2 [2.95–10.00]
EMD3: Dmt-(1S,2R)Achc-Phe-pFPhe-NH2 10 9 14 1.6 [1.02–2.11]
EMD4: Dmt-(1S,2R)Achc-Phe-(2S,3S)bMePhe-NH2 10 10 8 2.6 [0.31–4.81]
Morphine 9
Abbreviations: ED25: 25% effective dose after intrathecal administration. CI: confidence interval
Fig. 4. The dose-dependent effects of EM and derivatives (AUC values between 0–120 min)
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Discussion
We found that new EM-2 analogues with unnatural amino acids produced dose-dependent 
antinociception. In agreement with the in vitro results, the ligands with high potency at MOR 
and long half-life (EMD3 and EMD4) were the most effective in the in vivo tests (22). To our 
knowledge, we are also the first to prove the antinociceptive effects of intrathecally 
administered morphine and EM-2 in a MIA-induced osteoarthritis model. These data are in 
agreement with some earlier studies showing the antinociceptive effect of systemically 
administered morphine in this model (5, 40).
The modification of different opioid ligands is a well-known method for the enhancement 
of their antinociceptive potency. An earlier study showed that replacement of Tyr1 by Dmt 
resulted in marked increases in receptor-binding affinity and bioactivity in numerous opioid 
peptide agonists and antagonists (4). Replacement of Pro2 by alicyclic β-amino acids, 
pseudoprolines or piperidine-2-, -3- and -4-carboxylic acids resulted in increased affinity for 
the MOR and enhanced proteolytic stability (7, 14, 16, 35). The insertion of pFPhe in place 
of the Phe4 in enkephalin or endomorphins resulted in increased potency in functional assays 
(22, 38). Regarding the in vivo antinociceptive potency of endomorphin derivatives, several 
studies investigated the effects of different analogues after systemic or intracerebroventrical 
(i.c.v.) administration in acute pain tests, while only a few studies are available on the effects 
of derivatives at spinal level. Furthermore, no data were available about their effects in 
chronic pain models. Thus, different cyclic analogues of EM-2 induced more potent and/or 
prolonged antinociception in the hot-plate (HP) test after i.c.v. administration in mice 
compared to the parent ligand (17, 27, 29). EM analogues containing D-amino acids also 
induced effective antinociception in mice assessed in HP or tail-flick (TF) test after i.c.v. 
administration (21, 28). EM analogues containing other natural (e.g. arginine) or non-natural 
aminoacids (e.g. phenylglycine or homophenylalanine) had more prolonged and/or more 
potent antinociception in acute heat pain tests after i.c.v. administration in mice (8, 41, 43). 
A number of studies proved that in contrast to the parent ligands, some analogues could 
produce antinociception after peripheral administration, too, which suggests that these 
substances can pass thorugh the blood-brain barrier (27). A few studies found that analogues 
of EMs could antagonise opioid-induced antinociception after i.t. or i.c.v. administration in 
HP or TF tests in mice (33). 
EM-2 analogoues containing N-methylated amino acids consecutively in each position 
showed the strongest analgesic effect when administered centrally in the HP test in mice (18). 
An earlier study showed that a dimethyl-analogue of EM-2 (Dmt1-EM-2) produced 
antinociception after i.t. injection in formalin test (rat) (19). The effect evoked by Dmt1-EM-2 
was similar to the antinociceptive effect of EM-2 in the first phase but it was much stronger 
in the second phase. As for our results, we found that following the modification of the parent 
ligand at the 1st, 2nd and 4th positions by unnatural aminoacids the antinociceptive potency of 
these analogues remained. EMD1 and EMD2 which was modified in the 2nd and 4th positions 
had similar effects as EM-2, and this is in agreement with their Ki values for MOR, too (22). 
The insertion of 3 amino acids at the 1st, 2nd and 4th positions (EMD3 and EMD4) caused a 
considerable potency increase at MOR in vitro, and these ligands had also long half-life in a 
crude rat brain membrane homogenate (22). Therefore, the activation of the MOR and their 
high metabolic stability could have led to prolonged antinociception in our model. 
All of the above-mentioned studies applied acute heat or chemical pain models. 
However, osteoarthritis, a widespread condition, affects several million in the World 
accompanied by chronic pain. Intra-articular injection of MIA in the joint of rats disrupts 
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chondrocyte metabolism resulting in cartilage degeneration and subsequent nociceptive 
behavior that has been described as a model of osteoarthritis pain (3). An earlier study showed 
that systemic administration of morphine reversed the hind limb weight bearing decrease in 
this model (30). A recent study proved that MIA-induced joint pain was associated with 
significant changes in the spinal cord, too, that is associated with increased phosphorylation 
of mitogen activated protein kinases, and it was suggested that these changes were involved 
in nociceptie behaviors (20). Our study showed that intrathecally applied morphine, EM-2 
and derivatives can decrease the MIA-induced mechanical allodynia, supporting the role of 
the opioid receptors in the spinal cord in this type of pain as well.
To our knowledge, our results are the first to demonstrate that complex modification of 
endomorphins by introduction of Dmt, alicyclic b-amino acids, bMePhe, and pFPhe in the 
EM-2 can induce effective and prolonged antinociception in a chronic arthritis model. It is 
very important that the antinociceptive effects are in agreement with the binding experiments, 
that is, the ligands with high potency at MOR with long half-life (EMD3 and EMD4) were 
the most effective in the in vivo tests, too. These structural modifications of EM-2 might be 
a promising strategy to enhance bioavailability of peptides and may serve a role in the 
development of novel endomorphin analogues with increased therapeutic potential. Further 
studies are required to clarify the possible side-effects of these ligands.
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